TLSI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TLSI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
TriSalus Life Sciences has the GF Value Rank of 0.
GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of TriSalus Life Sciences's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Mary T Szela | director, officer: CEO and President | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
Sean Murphy | director, officer: Chief Financial Officer | C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703 |
Equity Ab Frankenius | 10 percent owner | BOX 984, BORAS V7 SE-501 10 |
Arjun Jj Desai | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Mats Wahlstrom | director, 10 percent owner | 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401 |
Bryan F. Cox | officer: Chief Scientific & Manufact. | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
George Kelly Martin | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Jodi Devlin | officer: President, Therapeutics | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Kerry R Hicks | director | C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228 |
James Alecxih | officer: President, Device Technology | C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065 |
Anil K. Singhal | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Steven C Katz | officer: Chief Medical Officer | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Von Eschenbach Andrew C. | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Richard Marshak | officer: Sr.VP, Corp. Dev. & Strategy | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Jennifer Stevens | officer: Chief Regulatory Officer | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
From GuruFocus
By Business Wire • 08-01-2024
By Business Wire • 05-06-2024
By GuruFocus News • 12-13-2024
By Business Wire • 03-21-2024
By Business Wire • 05-07-2024
By Business Wire • 08-15-2024
By Business Wire • 02-03-2025
By Business Wire • 11-11-2024
By GuruFocus News • 11-13-2024
By GuruFocus Research • 05-17-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.